Skip to content

Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street

Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00127062
Enrollment
60
Registered
2005-08-05
Start date
2003-05-31
Completion date
2006-08-31
Last updated
2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Exposure to Oxford Street, Exposure to Hyde Park

Brief summary

Acute exposure to diesel exhaust under normal city conditions leads to a worsening of symptoms of asthma, with reduction in lung function in asthmatic nonsmoking adults, dependent on the exposure dose and on the background severity of asthma. The worsening asthma is accompanied by increased oxidative stress and inflammation in the lungs.

Detailed description

The investigators will recruit 60 nonsmoking asthmatics of mild and of moderate severity. They will be exposed to Oxford St. or to Hyde Park for 2 hours each, at a walking pace. Real time exposure to PM2.5, carbon monoxide and nitrogen dioxide will be made each time. Health outcome measurements will be made before and after exposure to each street. Statistical analyses will be made to examine the effect of diesel exposure on changes in health outcome measures.

Interventions

OTHEROxford street

2 h walk around Oxford street

OTHERHyde park

2 h walk around Hyde park

Sponsors

Health Effects Institute
CollaboratorOTHER
Imperial College London
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

Subjects will be selected according to the current severity of their asthma; thirty from Steps 1 and 2 and thirty from Step 3 of the World Health Organization (WHO) Global Initiative for Asthma (GINA) asthma guidelines. These will include mild and moderate asthmatic states. Depending on baseline FEV1, subjects will undergo either a methacholine bronchial hyperresponsiveness assessment or airways reversibility testing. Subjects with normal FEV1 (\>80% predicted) or normal FEV1/FVC ratio will undergo methacholine challenge. Subjects with FEV1 \<80% predicted will undergo airways reversibility testing. Subjects must have either a PC20 of less than 8mg/ml methacholine, or improvement in FEV1 of 12% or more, following inhalation of short acting β-agonist (salbutamol 200μg from metered dose inhaler \[MDI\]). Skin prick testing will be conducted for common allergens (house dust mite, grass pollen, aspergillus fumigatus and cat hair). The results will only be for descriptive purposes, not as subject inclusion/

Exclusion criteria

. Subjects may be atopic or non-atopic (according to history and allergy testing).

Design outcomes

Primary

MeasureTime frame
Spirometry, Percentage Change in FEV1 From Baselinebaseline, 24 hours after

Participant flow

Pre-assignment details

Healthy volunteers were not recruited. Only asthma patients.

Participants by arm

ArmCount
Mild Asthma
Asthma patients with mild asthma
31
Moderate Asthma
Asthma patients with moderate asthma
29
Total60

Baseline characteristics

CharacteristicModerate AsthmaTotalMild Asthma
Age, Continuous34 years32 years31 years
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United Kingdom
29 participants60 participants31 participants
Sex: Female, Male
Female
15 Participants29 Participants14 Participants
Sex: Female, Male
Male
14 Participants31 Participants17 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 310 / 310 / 290 / 29
other
Total, other adverse events
0 / 310 / 310 / 290 / 29
serious
Total, serious adverse events
0 / 310 / 310 / 290 / 29

Outcome results

Primary

Spirometry, Percentage Change in FEV1 From Baseline

Time frame: baseline, 24 hours after

ArmMeasureValue (MEAN)
Mild Asthma Hyde ParkSpirometry, Percentage Change in FEV1 From Baseline-1.0 percentage change in FEV1 from baseline
Mild Asthma Oxford StreetSpirometry, Percentage Change in FEV1 From Baseline-4.8 percentage change in FEV1 from baseline
Moderate Asthma Hyde ParkSpirometry, Percentage Change in FEV1 From Baseline-2.2 percentage change in FEV1 from baseline
Moderate Asthma Oxford StreetSpirometry, Percentage Change in FEV1 From Baseline-7.4 percentage change in FEV1 from baseline
p-value: <0.05t-test, 2 sided
p-value: >0.05t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026